ResearcherChemRegen (United States)Active in the last 2 years
John Richard Cashman
Matched on ORCID iD 0000-0002-8628-9129; OpenAlex author ID A5028469156. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 3
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- Effect of PAWI-2 on pancreatic cancer stem cell tumors. Co-author DOI 10.1007/s10637-024-01447-x↗
- Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. First author DOI 10.1007/s10637-020-00998-z↗
- PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells. First author DOI 10.1038/s41598-020-65804-5↗
- Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. Last author PMID 30906636↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jiongjia Cheng · 3 shared papers, 2019–2021 · strength 0.63
- Paper Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker… DOI 10.1007/s10637-020-00998-z↗
- Paper PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic canc… DOI 10.1038/s41598-020-65804-5↗
- Paper Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. PMID 30906636↗
- Emily A. Cashman · 1 shared paper, 2024 · strength 0.46
- Andrew M. Lowy · 1 shared paper, 2019 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.